Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

September 20, 2020

Primary Completion Date

June 16, 2023

Study Completion Date

September 30, 2025

Conditions
COVID-19INTERFERONNEBULIZATION
Interventions
DRUG

inhaled type I interferon

The interventional arm includes inhaled interferon (9.6 MUI x2/d for 48 hours, then 9.6 MUI x1/d for 8 to 16 days or discharge), in addition to standard care. In phase B, maximum treatment duration is 8 days.

DRUG

WFI water nebulization

The interventional arm includes a WFI water nebulization comparator.

Trial Locations (7)

59208

CH de Tourcoing, Tourcoing

59322

CH de valenciennes, Valenciennes

60200

CH Compiègne-Noyon, Compiègne

62180

CH de l'Arrondissement de Montreuil-sur-mer, Rang-du-Fliers

80142

CH d'Abbeville, Abbeville

80480

CHU Amiens, Amiens

02100

CH de Saint-Quentin, Saint-Quentin

All Listed Sponsors
collaborator

CH TOURCOING

UNKNOWN

collaborator

CH ARROND DE MONTREUIL

UNKNOWN

collaborator

CH SAINT-QUENTIN

UNKNOWN

collaborator

CH Compiègne

UNKNOWN

collaborator

CH Abbeville

UNKNOWN

collaborator

CH VALENCIENNES

UNKNOWN

collaborator

Clinique Teissier

UNKNOWN

collaborator

University Hospital, Toulouse

OTHER

collaborator

University Hospital, Angers

OTHER_GOV

collaborator

CHU CAEN

UNKNOWN

collaborator

Nantes University Hospital

OTHER

lead

Centre Hospitalier Universitaire, Amiens

OTHER